These 3 Stocks Trounced the S&P 500 in the First Half of 2026 -- and Wall Street Thinks 1 of Them Could Soar Even More

Biotech names Moderna (MRNA), Revolution Medicines (RVMD), and Axsome Therapeutics (AXSM) each outperformed the S&P 500’s ~9% H1 2026 gain, driven by specific clinical/product catalysts. Moderna is set for an Aug. 5 regulatory decision on a flu vaccine and guides to up to ~10% revenue growth, though Wall Street expects ~40% downside over the next 12 months; Revolution gained on strong Phase 3 RAS-inhibitor data in metastatic pancreatic cancer (median survival 13.2 vs 6.7 months) but sees only ~+2% upside; Axsome is tipped to rise another ~13% as Auvelity won approval for agitation in Alzheimer’s and Symbravo supports additional growth.

Analysis

The market is rewarding biotech with visible, near-dated catalysts, but the dispersion matters more than the sector headline. AXSM looks like the cleanest operating leverage story because it already has a commercial base, so incremental prescription growth and a successful new indication can flow through to earnings faster than the market is likely modeling. By contrast, MRNA remains a sentiment trade: even if a new approval lands, it mostly stabilizes a post-pandemic franchise rather than resetting the long-term earnings power, so upside is likely capped unless management shows durable multi-product uptake.

RVMD is the highest-quality scientific story but also the most binary. The step from strong late-stage data to a durable rerating depends on regulatory path, label breadth, and whether oncology investors are willing to pay for a one-product pipeline when competition in targeted cancer therapeutics is intense. If the next readout or filing cadence slips, the stock can give back a lot of the move because the multiple is being driven more by anticipation than by cash flow.

Consensus appears to be missing that the best risk/reward is not necessarily the biggest data win, but the most monetizable launch sequence. AXSM has the best chance to convert approvals into recurring revenue over the next 1-3 quarters, while MRNA and RVMD are more likely to trade as event-driven momentum names. The key falsifier for the bullish AXSM view is slower-than-expected payer uptake or any sign the new indication is not incrementally accretive; for MRNA, a weak Aug. 5 decision or soft launch commentary would likely reopen the de-rating trend.

Key Decisions for Investors

• Long AXSM vs. short MRNA into the next 1-3 months: favor the name with commercialized products and multiple launch vectors over the one still trying to prove post-COVID durability; target a 15-20% relative outperformance if launch execution is credible.
• Buy AXSM on any post-news pullback rather than chasing momentum: use the next 2-4 weeks to scale in, because the valuation should re-rate on quarterly script data and launch commentary, not just the approval headline.
• Treat RVMD as a catalyst-trading position, not a core long: hold only into regulatory milestones, then trim on strength unless filing/label specifics clearly expand the addressable market; upside looks more limited than the data hype suggests.
• Avoid initiating fresh longs in MRNA ahead of the approval date unless you are specifically expressing a volatility view: the stock can pop on decision-day but still underperform over 6-12 months if sales mix and pipeline conversion do not improve.
• Watch XBI/IBB as sector proxies for a broader biotech rotation; if AXSM follows through while MRNA fades, a relative long AXSM / short XBI basket can capture stock-specific execution alpha with lower single-name binary risk.